Aptus Capital Advisors’s Intellia Therapeutics NTLA Stock Holding History

Aptus Capital Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,278	Closed	-$132K	–	1830
2026 Q1	$132K	Buy	10,278 +138	+1%	+$1.76K	﹤0.01%	1088
2025 Q4	$91.2K	Sell	10,140 -61,341	-86%	-$844K	﹤0.01%	1196
2025 Q3	$1.23M	Sell	71,481 -3,742	-5%	-$46.1K	0.01%	518
2025 Q2	$706K	Sell	75,223 -13,859	-16%	-$114K	0.01%	606
2025 Q1	$633K	Sell	89,082 -50,196	-36%	-$507K	0.01%	586
2024 Q4	$1.62M	Buy	+139,278	New	+$2.17M	0.02%	428

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Aptus Capital Advisors's NTLA Position: Q2 2026 in Review

Aptus Capital Advisors sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 10,278 shares — an estimated $132K sold.

Aptus Capital Advisors first reported a position in NTLA in Q4 2024 and held it in 6 quarters. The position peaked at $1.62M in Q4 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Aptus Capital Advisors reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
Aptus Capital Advisors sold 10,278 Intellia Therapeutics shares in Q2 2026, an estimated $132K.
Aptus Capital Advisors first reported a position in Intellia Therapeutics in Q4 2024 and held it in 6 quarters.
Aptus Capital Advisors's Intellia Therapeutics position peaked at $1.62M in Q4 2024.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.